GlassScriptPhysician profile
Kacey Cotoli Gibson
NPI 1366640310
$6,293.23
in general payments reported to CMS, 2019-2025
39 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2021: $668 · 2022: $1,037 · 2023: $1,310 · 2024: $1,736 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,437.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,186.99 | 2021-2025 | |
| Pfizer INC. | $765.24 | 2019-2025 | |
| Novo Nordisk INC | $757.17 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $552.91 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $433.82 | 2021-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $287.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $287.26 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Axsome Therapeutics, INC. | $175.30 | 2023-2025 | Auvelity, Symbravo |
| Dexcom, INC. | $155.51 | 2023-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $131.05 | 2019-2025 | Glassia, Trintellix |
| Radius Health, INC. | $128.18 | 2021-2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $121.53 | 2021-2025 | Spravato, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.90 | 2024-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $109.89 | 2019-2025 | Zoryve |
| Exact Sciences Corporation | $106.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kacey Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.